AR112353A1 - Compuesto de insulina acilada - Google Patents
Compuesto de insulina aciladaInfo
- Publication number
- AR112353A1 AR112353A1 ARP180101254A AR112353A1 AR 112353 A1 AR112353 A1 AR 112353A1 AR P180101254 A ARP180101254 A AR P180101254A AR 112353 A1 AR112353 A1 AR 112353A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- acillated
- insulin compound
- relate
- acylated insulin
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 3
- -1 INSULIN COMPOUND Chemical class 0.000 title 1
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente solicitud se refiere a compuestos descritos que se refieren al tratamiento de diabetes y/o hiperglucemia. Más particularmente, los compuestos descritos se refieren a compuestos de insulina acilados que reducen la glucosa en sangre, las composiciones farmacéuticas que contienen tales compuestos, los usos terapéuticos de dichos compuestos, y un compuesto intermediario usado para preparar los compuestos de insulina acilados. Reivindicación 1: Un compuesto, caracterizado porque es de la fórmula (1), en donde Xaa es el aminoácido glicina o asparagina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511690P | 2017-05-26 | 2017-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112353A1 true AR112353A1 (es) | 2019-10-23 |
Family
ID=62528889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101254 AR112353A1 (es) | 2017-05-26 | 2018-05-11 | Compuesto de insulina acilada |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10400021B2 (es) |
| EP (1) | EP3630165B1 (es) |
| JP (1) | JP6665349B2 (es) |
| KR (1) | KR102271057B1 (es) |
| CN (1) | CN110691608B (es) |
| AR (1) | AR112353A1 (es) |
| AU (1) | AU2018273777B2 (es) |
| BR (1) | BR112019021668A2 (es) |
| CA (1) | CA3065078C (es) |
| CL (1) | CL2019003259A1 (es) |
| CO (1) | CO2019012964A2 (es) |
| CR (1) | CR20190523A (es) |
| DO (1) | DOP2019000296A (es) |
| EA (1) | EA038073B1 (es) |
| EC (1) | ECSP19083930A (es) |
| IL (1) | IL270813B2 (es) |
| JO (1) | JOP20190273A1 (es) |
| MA (1) | MA49310A (es) |
| MX (1) | MX375982B (es) |
| PE (1) | PE20191836A1 (es) |
| PH (1) | PH12019502655A1 (es) |
| SA (1) | SA519410448B1 (es) |
| TW (1) | TWI672315B (es) |
| WO (1) | WO2018217573A1 (es) |
| ZA (1) | ZA201906955B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3893934B1 (en) | 2018-12-11 | 2025-09-10 | Sanofi | Insulin conjugates |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| BR112022013009A2 (pt) * | 2019-12-30 | 2022-09-06 | Gan & Lee Pharmaceuticals Co Ltd | Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina |
| CA3177905A1 (en) * | 2020-05-15 | 2021-11-18 | Eli Lilly And Company | Extended time action acylated insulin compounds |
| AU2023272483A1 (en) | 2022-05-18 | 2024-12-12 | Protomer Technologies Inc. | Aromatic boron-containing compounds and related insulin analogs |
| WO2024051787A1 (zh) * | 2022-09-09 | 2024-03-14 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010024556A (ko) * | 1997-10-24 | 2001-03-26 | 피터 지. 스트링거 | 불용성 인슐린 조성물 |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| EP2107069B1 (en) * | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| EP1846447B1 (en) | 2005-02-02 | 2013-08-21 | Novo Nordisk A/S | Insulin derivatives |
| EP2178912B1 (en) * | 2007-08-15 | 2015-07-08 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| JP5721432B2 (ja) * | 2007-08-15 | 2015-05-20 | ノボ・ノルデイスク・エー／エス | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン |
| JP5749155B2 (ja) * | 2008-03-18 | 2015-07-15 | ノボ・ノルデイスク・エー／エス | プロテアーゼ安定化アシル化インスリンアナログ |
| EP2376520B1 (en) * | 2008-12-19 | 2014-02-12 | Indiana University Research&Technology Corporation | Insulin analogs |
| CN105188736A (zh) | 2013-03-20 | 2015-12-23 | 诺和诺德股份有限公司 | 胰岛素给药方案 |
| EP2991672A1 (en) * | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
-
2017
- 2017-06-16 JO JOP/2019/0273A patent/JOP20190273A1/ar unknown
-
2018
- 2018-05-11 TW TW107116025A patent/TWI672315B/zh active
- 2018-05-11 AR ARP180101254 patent/AR112353A1/es unknown
- 2018-05-18 CA CA3065078A patent/CA3065078C/en active Active
- 2018-05-18 CN CN201880034670.1A patent/CN110691608B/zh active Active
- 2018-05-18 MX MX2019014086A patent/MX375982B/es active IP Right Grant
- 2018-05-18 EP EP18729289.1A patent/EP3630165B1/en active Active
- 2018-05-18 AU AU2018273777A patent/AU2018273777B2/en active Active
- 2018-05-18 BR BR112019021668-5A patent/BR112019021668A2/pt active IP Right Grant
- 2018-05-18 US US15/983,167 patent/US10400021B2/en active Active
- 2018-05-18 PE PE2019002403A patent/PE20191836A1/es unknown
- 2018-05-18 IL IL270813A patent/IL270813B2/en unknown
- 2018-05-18 MA MA049310A patent/MA49310A/fr unknown
- 2018-05-18 WO PCT/US2018/033418 patent/WO2018217573A1/en not_active Ceased
- 2018-05-18 KR KR1020197034368A patent/KR102271057B1/ko active Active
- 2018-05-18 EA EA201992272A patent/EA038073B1/ru unknown
- 2018-05-18 CR CR20190523A patent/CR20190523A/es unknown
- 2018-05-18 JP JP2019520536A patent/JP6665349B2/ja active Active
-
2019
- 2019-08-01 US US16/529,095 patent/US10597436B2/en active Active
- 2019-10-22 ZA ZA2019/06955A patent/ZA201906955B/en unknown
- 2019-10-31 SA SA519410448A patent/SA519410448B1/ar unknown
- 2019-11-14 CL CL2019003259A patent/CL2019003259A1/es unknown
- 2019-11-19 CO CONC2019/0012964A patent/CO2019012964A2/es unknown
- 2019-11-22 DO DO2019000296A patent/DOP2019000296A/es unknown
- 2019-11-25 EC ECSENADI201983930A patent/ECSP19083930A/es unknown
- 2019-11-25 PH PH12019502655A patent/PH12019502655A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112353A1 (es) | Compuesto de insulina acilada | |
| CO2019006017A2 (es) | Composiciones farmacéuticas que contienen insulina | |
| CL2025000631A1 (es) | Compuestos de insulina acilada de acción temporal prolongada | |
| ECSP19030002A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| AR098576A1 (es) | Producto farmacéutico | |
| MX2019007071A (es) | Novedosos derivados del acido fenilpropionico y usos de los mismos. | |
| PE20151595A1 (es) | Compuestos de pirazol-amida y sus usos farmaceuticos | |
| BR112013001301A2 (pt) | processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| CL2020000310A1 (es) | Análogos de insulina acilados novedosos y usos de estos. | |
| CL2023000086A1 (es) | Análogos de insulina novedosos y usos de estos(div 202201400) | |
| CL2021000938A1 (es) | Composiciones estables de semaglutida y usos de las mismas | |
| ECSP24000004A (es) | Derivados de 3(1oxoisoindolin2il)piperidina2,6diona y sus usos médicos | |
| ECSP23076800A (es) | Derivados de pirazolopiridina y sus usos | |
| UY33568A (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| MX2024004333A (es) | Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas. | |
| UY36098A (es) | Compuesto 1,1?-adipoilbis(pirrolidina-2-carboxilato) de (2r,2?r)-bis(((((tetrahidro-2h-piran-4- il)oxi)carbonil)oxi)metilo), para el tratamiento de la amiloidosis sistémica. | |
| BR102018010523A2 (pt) | peptídeo, composição farmacêutica compreendendo o mesmo e uso | |
| EA201891761A1 (ru) | Новые биароматические соединения пропинила, фармацевтические и косметические композиции, их содержащие, и их применение | |
| ES2363975B8 (es) | Uso de la yesotoxina. análogos y derivados para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y beta-amiloide. | |
| TH172399A (th) | การบำบัดโรคเบาหวานด้วยสูตรผสมอินซูลินที่ออกฤทธิ์นาน | |
| RU2016119040A (ru) | Способ лечения сахарного диабета второго типа и его кожных осложнений | |
| MX385095B (es) | Composiciones farmaceuticas orales para uso en dislipidemias. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |